alanine and safinamide

alanine has been researched along with safinamide in 129 studies

Research

Studies (129)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (6.20)	18.2507
2000's	14 (10.85)	29.6817
2010's	58 (44.96)	24.3611
2020's	49 (37.98)	2.80

Authors

Authors	Studies
Arand, M; Castelli, MG; Colombo, M; Dostert, P; Marrari, P; Oesch, F; Strolin Benedetti, MS	1
Dostert, P; Marrari, P; Martignoni, M; Poggesi, I; Rocchetti, M; Strolin Benedetti, M; Tocchetti, P	1
Bonsignori, A; Colombo, M; Dostert, P; Fariello, RG; Heidempergher, F; McArthur, RA; Pevarello, P; Pinciroli, V; Post, C; Salvati, P; Varasi, M	1
Bonsignori, A; Cervini, MA; Fariello, RG; Maj, R; Marrari, P; McArthur, RA; Pevarello, P; Post, C; Salvati, P; Varasi, M; White, HS; Wolf, HH; Woodhead, JW	1
Fariello, RG; Maj, R; McArthur, RA; Pevarello, P; Salvati, P; Ukmar, G; Varasi, M	1
Caccia, C; Cervini, MA; Faravelli, L; Fariello, RG; Fornaretto, MG; Lamberti, E; Maj, R; Mancinelli, E; Mazzanti, M; Pevarello, P; Salvati, P; Skeen, GA; Varasi, M; White, HS; Wolf, HH	1
Bonsignori, A; Caccia, C; Maj, R; McArthur, RA; Pevarello, P; Salvati, P; Traquandi, G; Varasi, M	1
Fariello, RG; Maj, R; McArthur, RA; Pevarello, P; Salvati, P; Varasi, M	1
Algate, C; Beard, D; Fariello, RG; Maj, R; Marrari, P; Salvati, P	1
Chazot, PL	2
Caccia, C; Cattaneo, C; Crivelli, F; Dal Bo, L; Fariello, RG; Ismaili, S; Marzo, A; Monti, NC	1
Arnold, G; Bonuccelli, U; Cattaneo, C; Fariello, RG; Kwiecinski, H; Onofrj, M; Sala, P; Stocchi, F; Szczudlik, A; Thomas, A; Van Dijk, A	1
Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P	1
Battaglia, G; Cattaneo, C; De Pandis, MF; Fariello, RG; Grassini, P; Stocchi, F; Vacca, L	1
Fariello, RG	1
Dal Bo, L; Fibbioli, M; Marzo, A; Mazzucchelli, P	1
Caccia, C; Capaldi, C; Carotti, A; Cellamare, S; Leonetti, F; Muncipinto, G; Nicolotti, O; Pisani, L; Stefanachi, A	1
Binda, C; Caccia, C; Carotti, A; Edmondson, DE; Mattevi, A; Pisani, L; Salvati, P; Wang, J	1
Chen, JJ; Fernandez, HH	1
Bonanni, L; Onofrj, M; Thomas, A	1
Kohn, H; Salomé, C; Salomé-Grosjean, E; Stables, JP	1
Ravikumar, K; Sridhar, B	1
Schapira, AH	1
Du, Y; Liu, W; Meng, J; Shi, X; Xue, N; Zhang, K	1
Di Stefano, AF; Rusca, A	1
Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F	1
Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A	1
Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lorenzana, P; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F	1
Fauchoux, N; Gallemann, D; Hermann, R; Johne, A; Krösser, S; Marquet, A; Wolna, P	1
Collins-Praino, LE; Lobianco, C; Podurgiel, S; Randall, PA; Roach, A; Salamone, JD; Yohn, S	1
Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M	1
Bechtold, D; Chauhdry, S; Hassoon, P; Lee, W; Malpass, K; Morsali, D; Palchaudhuri, U; Piers, T; Pocock, J; Roach, A; Smith, KJ; Snell, DM	1
Müller, T	4
Assandri, A; Brunner, M; Leuratti, C; Müller, M; Sardina, M; Ventura, P	1
Anand, R; Bhatt, M; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J	1
Dézsi, L; Vécsei, L	1
Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J	1
Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA	1
Dustrude, ET; Khanna, R; Kohn, H; Park, KD; Ripsch, MS; Wang, Y; White, FA; Yang, XF	1
Dahiya, N; Kakkar, AK	1
Deeks, ED	1
Mullali, G; Piers, T; Pocock, JM; Roach, A; Sadeghian, M; Smith, KJ	1
Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M	1
Abreu, D; Fabbri, M; Ferreira, JJ; Rosa, MM	1
Perez-Lloret, S; Rascol, O	1
Bonizzoni, E; Cattaneo, C; Sardina, M	1
Stocchi, F; Torti, M	1
Foley, P; Müller, T	1
Barone, P; Bonizzoni, E; Cattaneo, C; Sardina, M	1
Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH	1
Blair, HA; Dhillon, S	1
Hui, W; Sun, L; Zhang, H; Zhu, Z; Zou, L; Zou, Q	1
deSouza, RM; Schapira, A	1
Aschenbrenner, DS	1
Alcaro, S; Bagetta, D; Borges, F; Fonseca, A; Matos, MJ; Ortuso, F; Reis, J; Silva, T; Uriarte, E	1
Bonizzoni, E; Cattaneo, C; Keywood, C; Kottakis, I; Lazzeri, G; Müller, T	1
Alonso-Navarro, H; Jiménez-Jiménez, FJ; Valle-Arcos, D	1
Kulisevsky, J; Pagonabarraga, J	1
Brugnoli, A; Caccia, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sardina, M; Vailati, S	1
Bowles, K; Bradshaw, A; Meosky, K; Mospan, C; Mospan, G; Vance, S	1
Liguori, C; Mercuri, NB; Pierantozzi, M; Stefani, A	1
Gago, MF; Magalhães, R; Marques, P; Moreira, PS; Salgado, AJ; Sousa, N; Teixeira, FG	1
Borellini, L; Comi, C; Di Fonzo, A; Lacerenza, M; Lazzeri, G; Mancini, F; Silani, V	1
Castellani, P; Cattaneo, C; Kulisevsky, J; Tubazio, V	1
Finn, LA; Hussar, DA	1
Liguori, C; Mercuri, NB; Pierantozzi, M; Ruffini, R; Stefani, A	1
Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J	1
Akhter, S; Malik, SH; Qureshi, AR; Rana, AQ; Rana, R; Rizvi, SFH; Sarfraz, Z; Vannabouathong, C	1
Alborghetti, M; Nicoletti, F	1
Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S	1
Bianchi, MLE; Mauri, M; Riboldazzi, G; Versino, M	1
Cabo-López, I; Puy-Núñez, A	1
Ågren, H; Chiotis, K; Lemoine, L; Murugan, NA; Nordberg, A; Rodriguez-Vieitez, E	1
Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A	1
Bonizzoni, E; Cattaneo, C; Jost, WH	1
Bruno, V; Farcy, N; Karnik, V; Zamorano, C	1
Bentivoglio, AR; Di Stasio, E; Fusco, D; Laudisio, A; Lo Monaco, MR; Onder, G; Petracca, M; Ricciardi, D; Vetrano, DL; Zuccalà, G	1
Brugnoli, A; Caccia, C; Keywood, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Vailati, S	1
Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S	1
Altamura, C; Caccia, C; Carratù, MR; Conte, D; De Bellis, M; De Luca, A; Desaphy, JF; Farinato, A; Imbrici, P; Keywood, C; Melloni, E; Padoani, G; Pierno, S; Tarantino, N; Vailati, S	1
Parambi, DGT	1
Abdelalem Aziz Ahmed, M	1
Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A	2
Bovi, T; Di Vico, IA; Geroin, C; Segatti, A; Squintani, G; Tinazzi, M	1
Ishida, T; Koebisu, M	1
Kong, S; Sun, R; Wei, G; Xu, T	1
Alborghetti, M; Bianchini, E; Galli, S; Giovannelli, M; Pontieri, FE; Rinaldi, D; Salvetti, M; Sforza, M	1
Heidarian, S; Motaghinejad, M; Safari, S; Sepehr, A; Taheri, F	1
El-Kosasy, AM; Hussein, LA; Mohamed, NM; Salama, NN	1
Bhowmick, SS; Fox, SH; Gonzalez-Latapi, P; Saranza, G	1
Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M	1
Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G	1
Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T	1
Chen, KZ; Hao, GF; Jin, CF; Wang, ZZ; Xu, TF	1
Kh, R; Singh, D; Wasan, H	1
Carrara, F; Corrù, F; Elia, AE; Fittipaldo, VA; Giossi, R; Lo Re, F; Mazzari, M; Pani, A; Scaglione, F; Schicchi, A; Senatore, M; Tramacere, I	1
De Mase, A; De Micco, R; Giordano, A; Satolli, S; Siciliano, M; Tedeschi, G; Tessitore, A	1
Abbruzzese, G; Barone, P; Lopiano, L; Stocchi, F	1
Alborghetti, M; Bianchini, E; De Carolis, L; Della Gatta, F; Pontieri, FE; Rinaldi, D; Sforza, M	1
Chen, JB; Dai, Y; Duan, QN; Huang, QX; Jin, YJ; Li, JZ; Qian, L; Sun, X	1
Caccia, C; Jost, WH; Pagonabarraga, J; Tinazzi, M	1
Bosco, D; De Bartolo, M; Ettore, M; Fava, A; Gorgone, G; Iannacchero, R; Plastino, M; Scarfone, R; Vaccaro, A	1
Elkamhawy, A; Hassan, AHE; Kim, HJ; Lee, K; Paik, S; Park, JH; Park, KD; Roh, EJ	1
Dinda, AK; Joshi, B; Reeta, KH; Sharma, U; Singh, D; Wasan, H	1
Falkenburger, B; Grigoriou, S; Hausbrand, D; Leta, V; Martínez-Martín, P; Odin, P; Ray Chaudhuri, K; Reichmann, H; Rukavina, K	1
Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y	1
Alonso Losada, MG; Cabo López, I; Cimas Hernando, MI; Gonzalez Palmás, MJ; Labandeira, CM; Martínez Miró, C; Paz González, JM; Santos García, D; Yáñez Baña, R	1
Alonso Losada, MG; Cabo López, I; Cimas Hernando, MI; Cores Bartolomé, C; Gonzalez Palmás, MJ; Labandeira Guerra, C; Martínez Miró, C; Paz González, JM; Santos García, D; Yáñez Baña, R	1
Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y	1
Larson, D; Simuni, T	1
Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M	1
Chen, W; Gu, X; Liu, X; Qin, Z; Yin, M; Zhang, G; Zhang, Y	1
Hattori, N; Ishida, T; Kamei, T; Koebis, M; Nomoto, M; Suzuki, I; Tsuboi, Y	1
Alonso-Cánovas, A; Baena-Álvarez, B; Beltrán-Corbellini, Á; Chico-García, JL; López-Sendón, JL; Martínez-Castrillo, JC; Pagonabarraga, J; Pareés, I; Parra-Díaz, P; Pérez-Torre, P; Rodríguez-Jorge, F	1
Huot, P; Lachance, L	1
Hattori, N; Ishida, T; Kamei, T; Nomoto, M; Suzuki, I; Tsuboi, Y	1
Cerroni, R; De Masi, C; Fernandes, M; Garasto, E; Liguori, C; Mercuri, NB; Pierantozzi, M; Spanetta, M; Stefani, A	1
Abdellatef, HE; El-Abassy, OM; El-Sayed, HM; Hendawy, HAM; Ibrahim, H	1
Hirano, M; Isono, C; Nagai, Y; Samukawa, M	1
Cattaneo, C; Jing, S; Leuratti, C; Vaja, V; Yuan, Y	1
Ishida, T; Kobayashi, Y; Koebis, M; Kogo, Y; Maeda, T	1

Reviews

36 review(s) available for alanine and safinamide

Article	Year
Safinamide (Newron Pharmaceuticals). Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:6 Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Contraindications; Epilepsy; Humans; Parkinson Disease; Structure-Activity Relationship	2001
Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E. Drugs in R&D, 2004, Volume: 5, Issue:6 Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epilepsy; Humans; Parkinson Disease	2004
Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology, 2006, Oct-10, Volume: 67, Issue:7 Suppl 2 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Brain Ischemia; Disease Models, Animal; Gerbillinae; Humans; Kainic Acid; Levodopa; Mice; MPTP Poisoning; Neurons; Rats; Veratridine	2006
Safinamide. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007, Volume: 4, Issue:1 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Clinical Trials as Topic; Epilepsy; Humans; Parkinson Disease	2007
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Current opinion in investigational drugs (London, England : 2000), 2007, Volume: 8, Issue:7 Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Epilepsy; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Restless Legs Syndrome	2007
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy, 2007, Volume: 27, Issue:12 Pt 2 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2007
An expert opinion on safinamide in Parkinson's disease. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:7 Topics: Alanine; Animals; Benzylamines; Drug Design; Drug Tolerance; Humans; Neuroprotective Agents; Parkinson Disease	2008
Safinamide in the treatment of Parkinson's disease. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:13 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; Humans; Parkinson Disease; Treatment Outcome	2010
Current status of safinamide for the drug portfolio of Parkinson's disease therapy. Expert review of neurotherapeutics, 2013, Volume: 13, Issue:9 Topics: Alanine; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Humans; Parkinson Disease	2013
Safinamide for the treatment of Parkinson's disease. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:5 Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome	2014
Safinamide for the treatment of Parkinson's disease. Expert review of clinical pharmacology, 2014, Volume: 7, Issue:6 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease	2014
Management of Parkinson׳s disease: Current and future pharmacotherapy. European journal of pharmacology, 2015, Mar-05, Volume: 750 Topics: Adenosine A2 Receptor Antagonists; Alanine; Animals; Benzylamines; Drug Therapy; Humans; Levodopa; Parkinson Disease	2015
Safinamide: first global approval. Drugs, 2015, Volume: 75, Issue:6 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Cognition Disorders; Drug Approval; Dyskinesia, Drug-Induced; Humans; Internationality; Parkinson Disease	2015
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Neurodegenerative disease management, 2015, Volume: 5, Issue:6 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; Humans; Molecular Structure; Parkinson Disease	2015
Safinamide for symptoms of Parkinson's disease. Drugs of today (Barcelona, Spain : 1998), 2015, Volume: 51, Issue:11 Topics: Alanine; Animals; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease	2015
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. Expert review of neurotherapeutics, 2016, Volume: 16, Issue:3 Topics: Alanine; Animals; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease	2016
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. Drug design, development and therapy, 2016, Volume: 10 Topics: Adult; Aged; Alanine; Benzylamines; Double-Blind Method; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic	2016
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Clinical pharmacokinetics, 2017, Volume: 56, Issue:3 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease	2017
Safinamide: A Review in Parkinson's Disease. CNS drugs, 2017, Volume: 31, Issue:2 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life	2017
Safinamide for the treatment of Parkinson's disease. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:9 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:6 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease	2017
Safinamide: a new hope for Parkinson's disease? Drug discovery today, 2018, Volume: 23, Issue:3 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease	2018
▼ Safinamide for Parkinson's disease. Drug and therapeutics bulletin, 2018, Volume: 56, Issue:5 Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease	2018
Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology, 2018, Volume: 51, Issue:3-4 Topics: Alanine; Analgesics; Benzylamines; Electric Stimulation Therapy; Humans; Pain; Pain Management; Parkinson Disease	2018
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. Current neuropharmacology, 2019, Volume: 17, Issue:9 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline	2019
Current Status of Pain Management in Parkinson's Disease. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2020, Volume: 47, Issue:3 Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes	2020
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Combinatorial chemistry & high throughput screening, 2020, Volume: 23, Issue:9 Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation	2020
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease. F1000Research, 2019, Volume: 8 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic	2019
Safinamide in the treatment of Parkinson's disease. Neurodegenerative disease management, 2020, Volume: 10, Issue:4 Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Benzylamines; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Young Adult	2020
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. CNS drugs, 2020, Volume: 34, Issue:10 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Development; Drug Repositioning; Humans; Parkinson Disease; Purines; Zonisamide	2020
Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies. Brain research bulletin, 2021, Volume: 168 Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Nervous System Diseases; Parkinson Disease	2021
Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis. Clinical drug investigation, 2021, Volume: 41, Issue:4 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2021
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease. Drug design, development and therapy, 2021, Volume: 15 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Treatment Outcome	2021
The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 90 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Male; Middle Aged; Neurons; Parkinson Disease; Synaptic Transmission	2021
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease. Expert opinion on drug safety, 2022, Volume: 21, Issue:2 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Treatment Outcome	2022
New dopaminergic therapies for PD motor complications. Neuropharmacology, 2022, 02-15, Volume: 204 Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2022

Trials

24 trial(s) available for alanine and safinamide

Article	Year
Improvement of motor function in early Parkinson disease by safinamide. Neurology, 2004, Aug-24, Volume: 63, Issue:4 Topics: Adult; Aged; Alanine; Antiparkinson Agents; Benzylamines; Calcium Channel Blockers; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Diseases; Glutamic Acid; Humans; Male; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Sodium Channel Blockers; Treatment Outcome	2004
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology, 2006, Oct-10, Volume: 67, Issue:7 Suppl 2 Topics: Adult; Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pilot Projects; Treatment Outcome	2006
Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 384, Issue:6 Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Alanine; Benzylamines; Blood Pressure; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Tyramine	2011
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alanine; Analysis of Variance; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; International Cooperation; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index	2012
The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:4 Topics: Administration, Oral; Adult; Aged; Alanine; Benzylamines; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Tyramine; Young Adult	2012
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. European journal of neurology, 2013, Volume: 20, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index	2013
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects. Biopharmaceutics & drug disposition, 2012, Volume: 33, Issue:9 Topics: Adult; Alanine; Antifungal Agents; Antiparkinson Agents; Benzylamines; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Young Adult	2012
Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. Pharmacology, 2013, Volume: 92, Issue:3-4 Topics: Adult; Alanine; Benzylamines; Feces; Healthy Volunteers; Humans; Male; Parkinson Disease; Young Adult	2013
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:2 Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index	2014
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:10 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome	2014
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis. Journal of Parkinson's disease, 2015, Volume: 5, Issue:3 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Treatment Outcome	2015
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE. Journal of Parkinson's disease, 2016, Volume: 6, Issue:1 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome	2016
Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. Journal of Parkinson's disease, 2017, Volume: 7, Issue:1 Topics: Adult; Aged; Alanine; Benzylamines; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Parkinson Disease	2017
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA neurology, 2017, Feb-01, Volume: 74, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome	2017
Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. Journal of Parkinson's disease, 2017, Volume: 7, Issue:4 Topics: Alanine; Benzylamines; Double-Blind Method; Enzyme Inhibitors; Female; Humans; International Cooperation; Longitudinal Studies; Male; Mood Disorders; Outcome Assessment, Health Care; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors	2017
Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain. Advances in therapy, 2018, Volume: 35, Issue:4 Topics: Alanine; Antiparkinson Agents; Benzylamines; Chronic Pain; Double-Blind Method; Humans; Pain Management; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Time Factors	2018
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. Journal of Parkinson's disease, 2020, Volume: 10, Issue:1 Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index	2020
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study. Parkinsonism & related disorders, 2020, Volume: 75 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease	2020
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. Journal of Parkinson's disease, 2021, Volume: 11, Issue:1 Topics: Aged; Aged, 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies	2021
Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 91 Topics: Alanine; Benzylamines; Cross-Over Studies; Humans; Parkinson Disease; Pilot Projects; Polysomnography; REM Sleep Behavior Disorder	2021
Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study. Journal of the neurological sciences, 2021, 10-15, Volume: 429 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Pain; Parkinson Disease	2021
Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study. Journal of the neurological sciences, 2022, Mar-15, Volume: 434 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease	2022
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study. Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:10 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease; Treatment Outcome	2022
Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers. Clinical pharmacology in drug development, 2023, Volume: 12, Issue:11 Topics: Alanine; Benzylamines; East Asian People; Female; Humans; Male; Volunteers	2023

Other Studies

69 other study(ies) available for alanine and safinamide

Article	Year
The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. The Journal of pharmacy and pharmacology, 1994, Volume: 46, Issue:10 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Hydroxylation; In Vitro Techniques; Liver; Male; Mice; Mice, Inbred Strains; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; Testosterone	1994
Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. Progress in brain research, 1995, Volume: 106 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain Chemistry; Kinetics; Male; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley	1995
Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. Journal of medicinal chemistry, 1998, Feb-12, Volume: 41, Issue:4 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Bicuculline; Drug Design; Electroshock; Indicators and Reagents; Male; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Motor Activity; Picrotoxin; Postural Balance; Rats; Rats, Inbred Strains; Seizures; Structure-Activity Relationship; Strychnine	1998
Preclinical evaluation of PNU-151774E as a novel anticonvulsant. The Journal of pharmacology and experimental therapeutics, 1998, Volume: 285, Issue:2 Topics: Alanine; Animals; Anticonvulsants; Avoidance Learning; Benzylamines; Drug Tolerance; Male; Mice; Mice, Inbred ICR; Motor Activity; Rats; Rats, Sprague-Dawley; Rats, Wistar	1998
PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. European journal of pharmacology, 1998, Oct-16, Volume: 359, Issue:1 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Diazepam; Epilepsy; Hippocampus; Kainic Acid; Lamotrigine; Male; Neuroprotective Agents; Rats; Rats, Wistar; Triazines	1998
Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:3 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Calcium Channels; Glutamic Acid; Male; Membranes; Mice; Neurons; Patch-Clamp Techniques; Potassium Channels; Potassium Chloride; Rats; Rats, Wistar; Veratrine	1999
Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety. Bioorganic & medicinal chemistry letters, 1999, Jul-05, Volume: 9, Issue:13 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Dextromethorphan; Inhibitory Concentration 50; Kinetics; Mice; Rats	1999
Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures. Epilepsia, 1999, Volume: 40, Issue:11 Topics: Acetates; Alanine; Amines; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Benzylamines; Carbamazepine; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy, Complex Partial; Gabapentin; gamma-Aminobutyric Acid; Kindling, Neurologic; Lamotrigine; Male; Phenytoin; Rats; Rats, Wistar; Severity of Illness Index; Triazines	1999
Acute behavioral and EEG effects of NW-1015 on electrically-induced afterdischarge in conscious monkeys. Epilepsy research, 2000, Volume: 39, Issue:1 Topics: Alanine; Animals; Anticonvulsants; Behavior, Animal; Benzylamines; Electric Stimulation; Electroencephalography; Macaca fascicularis; Male; Phenytoin; Seizures	2000
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacological research, 2004, Volume: 50, Issue:1 Topics: Adolescent; Adult; Alanine; Anticonvulsants; Antiparkinson Agents; Area Under Curve; Benzylamines; Cytochrome P-450 Enzyme System; Diet; Dietary Fats; Dose-Response Relationship, Drug; Electrocardiography; Half-Life; Heart Rate; Humans; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Reproducibility of Results; Telemetry	2004
Bioassay of safinamide in biological fluids of humans and various animal species. Arzneimittel-Forschung, 2006, Volume: 56, Issue:12 Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Bile; Chromatography, High Pressure Liquid; Dogs; Haplorhini; Humans; Mass Spectrometry; Rats; Reproducibility of Results	2006
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. Journal of medicinal chemistry, 2007, Oct-04, Volume: 50, Issue:20 Topics: Alanine; Amides; Animals; Benzylamines; Binding Sites; In Vitro Techniques; Isoenzymes; Mitochondria; Models, Molecular; Monoamine Oxidase Inhibitors; Protein Binding; Rats; Stereoisomerism; Structure-Activity Relationship; Tetrahydroisoquinolines	2007
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. Journal of medicinal chemistry, 2007, Nov-15, Volume: 50, Issue:23 Topics: Alanine; Benzylamines; Coumarins; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding	2007
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities. Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Acetamides; Alanine; Amides; Amino Acids; Animals; Anticonvulsants; Benzylamines; Drug Evaluation, Preclinical; Lacosamide; Mice; Pain; Rats; Seizures; Structure-Activity Relationship; Treatment Outcome	2010
Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B. Acta crystallographica. Section C, Crystal structure communications, 2010, Volume: 66, Issue:Pt 6 Topics: Alanine; Benzylamines; Crystallization; Crystallography, X-Ray; Hydrogen Bonding; Monoamine Oxidase Inhibitors	2010
A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug. Journal of pharmaceutical and biomedical analysis, 2011, Apr-28, Volume: 55, Issue:1 Topics: Alanine; Antiparkinson Agents; Benzylamines; Calibration; Cellulose; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Hydrogen-Ion Concentration; Limit of Detection; Mesylates; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenylcarbamates; Quality Control; Reproducibility of Results; Stereoisomerism; Technology, Pharmaceutical	2011
Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacology, biochemistry, and behavior, 2013, Volume: 105 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Locomotion; Male; Muscarinic Agonists; Parkinsonian Disorders; Pilocarpine; Rats; Rats, Sprague-Dawley; Tremor	2013
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism & related disorders, 2013, Volume: 19, Issue:5 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome	2013
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain : a journal of neurology, 2013, Volume: 136, Issue:Pt 4 Topics: Alanine; Animals; Benzylamines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Flecainide; Male; Microglia; Multiple Sclerosis; Neuroprotective Agents; Rats; Sodium Channel Blockers	2013
Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamid ACS chemical neuroscience, 2015, Feb-18, Volume: 6, Issue:2 Topics: Acetamides; Alanine; Analgesics; Animals; Anticonvulsants; Benzylamines; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Female; Formaldehyde; Lacosamide; Male; Membrane Potentials; Mice; Neuralgia; Neurons; Patch-Clamp Techniques; Rats, Sprague-Dawley; Seizures; Tibial Nerve; Voltage-Gated Sodium Channel Blockers; Voltage-Gated Sodium Channels	2015
Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. Neuropathology and applied neurobiology, 2016, Volume: 42, Issue:5 Topics: Alanine; Animals; Benzylamines; Dopaminergic Neurons; Male; Microglia; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley	2016
Identification, Characterization, and Quantification of Impurities of Safinamide Mesilate: Process-Related Impurities and Degradation Products. Journal of AOAC International, 2017, Jul-01, Volume: 100, Issue:4 Topics: Alanine; Benzylamines; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Mesylates	2017
New Drug Approved For Parkinson's Disease. The American journal of nursing, 2017, Volume: 117, Issue:7 Topics: Alanine; Benzylamines; Contraindications, Drug; Drug Approval; Drug Labeling; Drug Therapy, Combination; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease	2017
Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis? Journal of medicinal chemistry, 2017, 08-24, Volume: 60, Issue:16 Topics: Alanine; Benzylamines; Chromones; Clorgyline; Coumarins; Humans; Indans; Kinetics; Ligands; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Selegiline; Structure-Activity Relationship	2017
Hypersexuality Possibly Associated With Safinamide. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:5 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Parkinson Disease; Sexual Behavior	2017
Safinamide (Xadago) for Parkinson's disease. The Medical letter on drugs and therapeutics, 2017, 09-11, Volume: 59, Issue:1529 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Treatment Outcome	2017
[Safinamide from daily clinical practice: first clinical steps]. Revista de neurologia, 2017, Nov-16, Volume: 65, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies	2017
Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. The Journal of pharmacology and experimental therapeutics, 2018, Volume: 364, Issue:2 Topics: Alanine; Animals; Basal Ganglia; Benzylamines; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Male; Neurons; Rats; Rats, Sprague-Dawley	2018
Drug updates and approvals: 2017 in review. The Nurse practitioner, 2017, Dec-15, Volume: 42, Issue:12 Topics: Adamantane; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Benzylamines; Dipeptides; Drug Approval; Drug Combinations; Glucosides; Humans; Oxymetazoline; Primary Health Care; United States; United States Food and Drug Administration	2017
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. Sleep medicine, 2018, Volume: 41 Topics: Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Restless Legs Syndrome; Treatment Outcome	2018
Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018, Volume: 39, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Treatment Outcome	2018
2018 New Drug Update. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2018, Apr-01, Volume: 33, Issue:4 Topics: Aged; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiparkinson Agents; Benzamides; Benzylamines; Constipation; Drug Approval; Humans; Natriuretic Peptides; Psoriasis; Pyridines; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study. Parkinsonism & related disorders, 2018, Volume: 57 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Sleep; Sleep Wake Disorders; Surveys and Questionnaires	2018
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study]. Fortschritte der Neurologie-Psychiatrie, 2018, Volume: 86, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies	2018
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia. The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:3 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction	2018
Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2019, Volume: 40, Issue:2 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Male; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome	2019
Hypersexuality associated with safinamide. Neurologia, 2020, Volume: 35, Issue:7 Topics: Alanine; Antiparkinson Agents; Benzylamines; Sexuality	2020
Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:6 Topics: Aged; Alanine; Alzheimer Disease; Benzylamines; Binding Sites; Brain; Computational Biology; Computer Simulation; Female; Humans; Ligands; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Docking Simulation; Monoamine Oxidase; Positron-Emission Tomography; Protein Binding; Protein Conformation; Radiopharmaceuticals; Retrospective Studies; tau Proteins	2019
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease. Acta neurologica Scandinavica, 2019, Volume: 140, Issue:1 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease	2019
Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study. Aging clinical and experimental research, 2020, Volume: 32, Issue:7 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Combined Modality Therapy; Hospitalization; Humans; Logistic Models; Middle Aged; Parkinson Disease; Retrospective Studies	2020
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease. Neuropharmacology, 2020, 05-01, Volume: 167 Topics: Alanine; Animals; Benzylamines; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley	2020
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease. Neuropharmacology, 2020, 06-15, Volume: 170 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar	2020
Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo. Experimental neurology, 2020, Volume: 328 Topics: Action Potentials; Alanine; Animals; Benzylamines; HEK293 Cells; Humans; Male; Muscle, Skeletal; Myotonia; NAV1.4 Voltage-Gated Sodium Channel; Rats; Rats, Wistar	2020
Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study. Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:8 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Quality of Life	2020
[Safinamide Mesilate (Equfina Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2020, Volume: 155, Issue:4 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Mesylates; Rats; Tablets	2020
The Protective Effect of Safinamide in Ischemic Stroke Mice and a Brain Endothelial Cell Line. Neurotoxicity research, 2020, Volume: 38, Issue:3 Topics: Alanine; Animals; Benzylamines; Blood-Brain Barrier; Brain; Brain Ischemia; Cells, Cultured; Endothelial Cells; Ischemic Stroke; Male; Matrix Metalloproteinase 2; Mice, Inbred C57BL; Reperfusion Injury; Stroke	2020
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study. Journal of the neurological sciences, 2020, 09-15, Volume: 416 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease	2020
The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. Aging clinical and experimental research, 2021, Volume: 33, Issue:6 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Parkinson Disease; Retrospective Studies	2021
Neuroprotective and neuro-survival properties of safinamide against methamphetamine-induced neurodegeneration: Hypothetic possible role of BDNF/TrkB/PGC-1α signaling pathway and mitochondrial uncoupling protein -2(UCP-2). Medical hypotheses, 2020, Volume: 143 Topics: Alanine; Benzylamines; Brain-Derived Neurotrophic Factor; Humans; Methamphetamine; Neuroprotection; Receptor, trkB; Signal Transduction; Uncoupling Protein 1; Uncoupling Protein 2	2020
New and validated RP-HPLC Method for Quantification of Safinamide Mesylate in Presence of Its Basic Degradate, Levodopa and Ondansetron: Application to Human Plasma. Journal of chromatographic science, 2020, Sep-29, Volume: 58, Issue:9 Topics: Alanine; Benzylamines; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Levodopa; Limit of Detection; Linear Models; Ondansetron; Reproducibility of Results; Tablets	2020
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study. European journal of neurology, 2021, Volume: 28, Issue:1 Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease	2021
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. Journal of neural transmission (Vienna, Austria : 1996), 2021, Volume: 128, Issue:2 Topics: Alanine; Antiparkinson Agents; Benzylamines; Executive Function; Humans; Levodopa; Parkinson Disease	2021
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor. Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Amides; Animals; Benzylamines; Binding Sites; Dopaminergic Neurons; Drug Design; Humans; Male; Mice, Inbred ICR; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Protein Binding; Structure-Activity Relationship	2020
Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:1 Topics: Alanine; Antiparkinson Agents; Behavioral Symptoms; Benzylamines; Cognition; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Prospective Studies; Quality of Life	2022
Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study. Neurological research, 2021, Volume: 43, Issue:11 Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Substitution; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies	2021
Safinamide prevents lipopolysaccharide (LPS)-induced inflammation in macrophages by suppressing TLR4/NF-κB signaling. International immunopharmacology, 2021, Volume: 96 Topics: Alanine; Anti-Inflammatory Agents; Benzylamines; Cyclooxygenase 2; Cytokines; Dinoprostone; Humans; Inflammation; Inflammation Mediators; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Signal Transduction; Toll-Like Receptor 4; U937 Cells	2021
Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies. Bioorganic chemistry, 2021, Volume: 115 Topics: Alanine; Benzylamines; Dose-Response Relationship, Drug; Drug Discovery; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship	2021
Post Stroke Safinamide Treatment Attenuates Neurological Damage by Modulating Autophagy and Apoptosis in Experimental Model of Stroke in Rats. Molecular neurobiology, 2021, Volume: 58, Issue:12 Topics: Alanine; Animals; Apoptosis; Autophagy; Benzylamines; Brain; Cytokines; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Motor Activity; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Sprague-Dawley; Stroke	2021
Effects of safinamide on pain in patients with fluctuating Parkinson's disease. Brain and behavior, 2021, Volume: 11, Issue:10 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Pilot Projects; Quality of Life	2021
Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR. Advances in therapy, 2021, Volume: 38, Issue:10 Topics: Aged; Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies	2021
Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:4 Topics: Aged; Alanine; Benzylamines; Disorders of Excessive Somnolence; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sleep; Sleep Wake Disorders	2022
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:5 Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome	2022
Safinamide protects against amyloid β (Aβ)-induced oxidative stress and cellular senescence in M17 neuronal cells. Bioengineered, 2022, Volume: 13, Issue:1 Topics: Alanine; Amyloid beta-Peptides; Benzylamines; Cell Line; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Humans; Models, Biological; Molecular Structure; Neurons; Neuroprotective Agents; Oxidative Stress; Plasminogen Activator Inhibitor 1	2022
Efficacy and safety of high doses of safinamide in advanced Parkinson disease. Parkinsonism & related disorders, 2022, Volume: 97 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease	2022
Pemphigoid-like Skin Lesions Following Introduction of Safinamide. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2023, Volume: 50, Issue:4 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Pemphigoid, Bullous	2023
Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study. Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:11 Topics: Alanine; Benzylamines; Fatigue; Female; Humans; Male; Pain; Parkinson Disease; Quality of Life	2022
Green Spectrophotometric Platforms for Resolving Overlapped Spectral Signals of Recently Approved Antiparkinsonian Drug (Safinamide) in the Presence of Its Synthetic Precursor (4-Hydroxybenzaldehyde): Applying Ecological Appraisal and Comparative Statisti Journal of AOAC International, 2022, Dec-22, Volume: 106, Issue:1 Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Parkinson Disease	2022
The effects of safinamide on dysphagia in Parkinson's disease. PloS one, 2023, Volume: 18, Issue:5 Topics: Alanine; Antiparkinson Agents; Benzylamines; Deglutition Disorders; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies	2023
Analgesic effect of safinamide mesylate in a rat model of neuropathic pain. Behavioural brain research, 2023, 08-24, Volume: 452 Topics: Alanine; Analgesics; Animals; Antiparkinson Agents; Benzylamines; Male; Mesylates; Monoamine Oxidase Inhibitors; Neuralgia; Parkinson Disease; Quality of Life; Rats	2023